SCHEMBL348420

SCHEMBL348420

COc1cc(OC)c2c(=O)[nH]c(-c3ccc(N4CCN(C)CC4)cc3)nc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.65
▸ ALDH1A1 P00352 3/20 0.65
▸ MAPT P10636 2/20 0.65
▸ BRD4 O60885 7/20 0.60
▸ BRD2 P25440 1/20 0.60
▸ CSNK1A1 P48729 1/20 0.60
▸ CSNK1D P48730 1/20 0.60
▸ CSNK1E P49674 1/20 0.60
▸ CSNK1G2 P78368 1/20 0.60
▸ BRD3 Q15059 1/20 0.60
▸ CSNK1G1 Q9HCP0 1/20 0.60
▸ TNKS O95271 1/20 0.56
▸ PARP1 P09874 1/20 0.56
▸ TNKS2 Q9H2K2 1/20 0.56
▸ IL17A Q16552 1/20 0.55
▸ HDAC3 O15379 6/20 0.54
▸ HDAC4 P56524 6/20 0.54
▸ HDAC1 Q13547 6/20 0.54
▸ HDAC7 Q8WUI4 6/20 0.54
▸ HDAC2 Q92769 6/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30053201 1.00 KDM4E (0.65) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL378252 0.96 KDM4E (0.61) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL30053496 0.90 BRD4 (0.58) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL378020 0.90 BRD4 (0.58) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL348652 0.90 BRD4 (0.58) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL30052318 0.89 BRD4 (0.55) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL377720 0.89 BRD4 (0.55) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL378038 0.89 BRD4 (0.55) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL377629 0.88 BRD4 (0.62) KDM4EALDH1A1MAPTBRD4BRD2
SCHEMBL377547 0.88 BRD4 (0.59) KDM4EALDH1A1MAPTBRD4BRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190091235-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2019-03-28 — — US claimed
US-10131640-B2 Anti-inflammatory agents RESVERLOGIX CORP. (CA) 2018-11-20 — — US claimed
US-10111885-B2 Compositions and therapeutic methods for the treatment of complement-associated diseases RESVERLOGIX CORP. (CA) 2018-10-30 — — US claimed
US-20180104245-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2018-04-19 — — US claimed
EP-3268007-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES Resverlogix Corp. (CA) 2018-01-17 — — EP claimed
US-20160346291-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION RESVERLOGIX CORP (CA) 2016-12-01 — — US claimed
WO-2016147053-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES RESVERLOGIX CORP. (CA) 2016-09-22 — — WO claimed
US-20160263126-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES HEPALINK (HONG KONG) LIMITED (HK) 2016-09-15 — — US claimed
CN-105859639-A NOVEL ANTI-INFLAMMATORY AGENTS 雷斯韦洛吉克斯公司 2016-08-17 — — CN claimed
EP-3035933-A2 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION Resverlogix Corporation (CA) 2016-06-29 — — EP claimed
US-9199990-B2 Compounds for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2015-12-01 — — US claimed
US-20150072955-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (US) 2015-03-12 — — US claimed
WO-2015025228-A2 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION RESVERLOGIX CORP. (CA) 2015-02-26 — — WO claimed
US-8889698-B2 Compounds for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2014-11-18 — — US claimed
US-20130281397-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION RVX THERAPEUTICS INC. (CA) 2013-10-24 — — US claimed
EP-2408454-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2012-01-25 — — EP claimed
US-20120015905-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. 2012-01-19 — — US claimed
US-8053440-B2 Compounds for the prevention and treatment of cardiovascular diseases Resverlogix Corporation (CA) 2011-11-08 — — US claimed
WO-2010106436-A2 NOVEL ANTI-INFLAMMATORY AGENTS RESVERLOGIX CORP. (CA) 2010-09-23 — — WO claimed
US-20080188467-A1 To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists HEPALINK (HONG KONG) LIMITED (HK) 2008-08-07 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180104245-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 KDM4E 4404/4885ALDH1A1 548/4885MAPT 3436/4885
US-10111885-B2 Compositions and therapeutic methods for the treatment of complement-associated diseases C5, CFH, C1QBP KDM4E 3741/4885ALDH1A1 2199/4885MAPT 2874/4885
US-20130281397-A1 TREATMENT OF DISEASES BY EPIGENETIC REGULATION BRD4, BMI1, BRPF3 KDM4E 202/4885ALDH1A1 4671/4885MAPT 2454/4885
US-20160346291-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION PCSK9, TGFB1, HMGCR KDM4E 1562/4885ALDH1A1 4669/4885MAPT 256/4885
US-20120015905-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 KDM4E 4404/4885ALDH1A1 548/4885MAPT 3436/4885
US-10131640-B2 Anti-inflammatory agents VCAM1, ICAM1, IL6 KDM4E 3982/4885ALDH1A1 587/4885MAPT 2112/4885
US-20150072955-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, HDLBP, FABP3 KDM4E 4404/4885ALDH1A1 548/4885MAPT 3436/4885
US-20160263126-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES C5, CFH, C1QBP KDM4E 3741/4885ALDH1A1 2199/4885MAPT 2874/4885
US-20190091235-A1 COMPOSITIONS AND THERAPEUTIC METHODS FOR THE TREATMENT OF COMPLEMENT-ASSOCIATED DISEASES C5, CFH, C1QBP KDM4E 3741/4885ALDH1A1 2199/4885MAPT 2874/4885
US-20080188467-A1 To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists APOB, LDLR, APOL1 KDM4E 2993/4885ALDH1A1 1784/4885MAPT 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback